News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

DxTerity Diagnostics and Caliper Life Sciences, Inc. (CALP) Partner to Deliver NEAT(R) Multiplex Assays on Caliper's LabChip(R) Dx Platform



10/24/2011 1:21:26 PM

LOS ANGELES and HOPKINTON, Mass., Oct. 24, 2011 /PRNewswire/ -- DxTerity Diagnostics, Inc. and Caliper Life Sciences, Inc. (NASDAQ: CALP) announced today that the companies have entered into a co-development and co-marketing strategic collaboration that will allow researchers to perform DxTerity's NEAT multiplex diagnostic assays on Caliper's LabChip Dx instrument platform minimizing sample processing time without compromising data quality. Caliper's future LabChip Dx instruments will include specific diagnostic identification, scoring and reporting software, developed in collaboration with DxTerity.

"We are excited to partner with Caliper. The LabChip Dx platform allows DxTerity's customers to directly analyze NEAT assays in minutes at a very low cost per assay. This is coupled with user friendly software and affordable instrument pricing," said Dr. Bob Terbrueggen, President and CEO of DxTerity Diagnostics. "DxTerity's simple and robust NEAT assays, combined with the ease-of-use of the Caliper LabChip Dx system, will eliminate significant barriers to the use of multiplex genomic tests in the clinical laboratory and lead to major gains in personalized medicine."

DxTerity's NEAT assays allow analysis of gene expression and detection of single nucleotide polymorphisms (SNPs) directly from blood or formalin-fixed paraffin embedded (FFPE) tissue samples, virtually eliminating complex sample preparation processes. Multiplex assays for up to 40 gene targets are routinely performed, delivering unique applications for clinical diagnostics and life science research. DxTerity's lead clinical product in development is a blood screening test that measures a patient's radiation exposure following a nuclear event, such as the recent disaster in Fukushima, Japan. The initial release of this product is scheduled for June of 2012. DxTerity is also developing low cost, blood-based cancer screening tests based upon the gene signature panels acquired from SourceMDx.

The LabChip Dx system is based on Caliper's patented microfluidic separation technology, and enables high-throughput multiplex analysis for discovery and validation of nucleic acid and protein biomarkers. The LabChip Dx system uses minimal sample volumes and enables automated sample processing and analysis, providing a robust and cost-effective platform that is achieving a high rate of adoption among diagnostic laboratories around the world.

"Caliper continues to develop innovative microfluidic solutions that uniquely enable molecular and companion diagnostics," said Kevin Hrusovsky, President and CEO of Caliper Life Sciences. "We believe this collaboration with DxTerity will result in a significant expansion of the number and type of tests available for readout by the LabChip Dx platform. DxTerity's NEAT platform represents a unique and valuable addition to the medical and life science fields by enabling low cost, direct-from-sample, simultaneous analysis of RNA gene expression and SNPs. These assays align with Caliper's vision for the future of medicine where molecular diagnostics are increasingly used to characterize disease and select the proper course of treatment."

About DxTerity Diagnostics Inc.

DxTerity Diagnostics is an emerging genomics platform company that has developed a revolutionary medical device that can perform complex genomic tests in one hour in the doctor's office. DxTerity's core technology platform is known as NEAT or Non-Enzymatic Amplification Technology. NEAT-based Solutions enable high value Genomic test for cancer or infectious diseases to be delivered quickly and efficiently, resulting in the timely delivery of essential diagnostic and prognostic information to medical personnel.

About Caliper Life Sciences, Inc.

Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technologies to bridge the gap between in vitro assays and in vivo results, enabling researchers to translate those results into cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information, please visit www.CaliperLS.com.

The LabChip Dx utilizes Caliper's innovative microfluidics technology to perform reproducible, high resolution, electrophoretic separations for analyzing multiplex PCR products.

The statements in this press release regarding future events, including the statements that (i) Caliper's future LabChip Dx instruments will include specific diagnostic software, (ii) DxTerity's NEAT assays, combined with Caliper's LabChip Dx system, will eliminate significant barriers to the use of multiplex genomic tests in the clinical laboratory and lead to major gains in personalized medicine, (iii) the initial release of a product based on a combination of a DxTerity NEAT assay and the LabChip Dx platform is scheduled for June of 2012, and (iv) Caliper believes that its collaboration with DxTerity will result in a significant expansion of the number and type of tests available for readout by the LabChip Dx platform, are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements as a result of a number of factors, including that the product development collaboration between Caliper and DxTerity may not result in the development of viable products, and even if such development efforts are successful, the developed products may not gain wide market acceptance and may face competition from other new competitive products. In addition, Caliper may encounter unanticipated difficulties in obtaining any required regulatory approvals for such products. Further information on risks faced by Caliper are detailed under the caption "Risks Related To Our Business" in Caliper's Annual Report on Form 10-K for the year ended December 31, 2010. Our filings are available on a web site maintained by the Securities and Exchange Commission at http://www.sec.gov. Caliper does not undertake any obligation to update forward-looking or other statements in this release.

Caliper and LabChip are registered trademarks of Caliper Life Sciences, Inc. DxTerity and NEAT are registered trademarks of DxTerity Diagnostics, Inc.

SOURCE Caliper Life Sciences, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES